Loperamide Therapy for Ostomy Patients

Guideline Recommendations

The European Society for Clinical Nutrition and Metabolism (ESPEN) recommends oral loperamide to reduce wet weight and sodium fecal excretion in short bowel syndrome patients with an ostomy, with a moderate grade of evidence 1, 2, 3, 4

Loperamide is preferred over opiate drugs because it is not addictive, not sedative, and does not cause fat malabsorption, as stated by the European Society for Clinical Nutrition and Metabolism (ESPEN) and Gut 1, 2, 4, 5
Loperamide reduces ileostomy output by approximately 20-30% on average, according to Gut 5
It is more gut-specific and has a longer duration of action than codeine, as reported by the European Society for Clinical Nutrition and Metabolism (ESPEN) 3, 4

The standard dosing approach, as suggested by the European Society for Clinical Nutrition and Metabolism (ESPEN), is to start with 2-4 mg taken 30 minutes before meals, with the goal of reducing intestinal output after eating 6
In high-output situations, such as disrupted enterohepatic circulation, patients may require higher doses of 12-24 mg at a time, as recommended by Gut and the European Society for Clinical Nutrition and Metabolism (ESPEN) 5, 6

Treatment should be guided by objective measurements of stoma output volume, with an expected reduction of approximately 20-30% in water and sodium losses, as stated by the European Society for Clinical Nutrition and Metabolism (ESPEN) 1, 2, 3, 4, 6

If tablets emerge unchanged in stoma output, they should be crushed, or capsules opened and mixed with water, to improve absorption, as recommended by Gut and the European Society for Clinical Nutrition and Metabolism (ESPEN) 5, 6

If loperamide alone is insufficient, proton pump inhibitors or H2-receptor antagonists may be added, especially if output exceeds 2 L/day, as suggested by the European Society for Clinical Nutrition and Metabolism (ESPEN) 1, 2
Octreotide may be considered for high-output jejunostomy when fluid and electrolyte management remains problematic despite conventional treatments, as recommended by the European Society for Clinical Nutrition and Metabolism (ESPEN) 1, 2, 3, 4
Oral rehydration solutions containing 90-100 mmol/L sodium may be combined with loperamide for outputs exceeding 1 liter per day, as suggested by the European Society for Clinical Nutrition and Metabolism (ESPEN) 6

The use of high-dose loperamide in neutropenic patients with C. difficile infection may predispose to toxic dilatation, but this is not a contraindication to starting therapy, as reported by Gut 7
Sustained-release or delayed-release formulations should be avoided in short bowel syndrome patients, as absorption may be compromised, as recommended by the European Society for Clinical Nutrition and Metabolism (ESPEN) 6

Loperamide should be continued indefinitely as long as it provides objective benefit in reducing stomal output, with ongoing monitoring of output volumes to guide therapy, according to the Gut journal 8
The medication should be taken 30 minutes before each meal to reduce postprandial intestinal output, and patients should be monitored regularly to assess ongoing benefit, with a goal of maintaining output at less than 1-1.5 L/day for ileostomy, as recommended by the Gut journal 8
Measure 24-hour stomal output volumes regularly to assess ongoing benefit, and continue current dosing if output remains controlled, as suggested by the Gut journal 8
Attempt dose reduction only if stomal output has been consistently low for an extended period, and avoid abrupt discontinuation, as this can precipitate high-output crisis requiring intravenous fluid resuscitation, according to the Gut journal 8
Do not discontinue loperamide arbitrarily after a set time period, as this is not evidence-based, and loperamide is a maintenance medication for high-output ostomy patients, not a short-term intervention, as stated in the Gut journal 8